EUVIMEDEUVIMED entdecken
Fallbericht

Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation

Bruno Almeida Costa, Paulino Tallón de Lara, Wungki Park, Fergus Keane, James J Harding, Danny N Khalil

Oncology Research and Treatment · 2023

DOI: 10.1159/000529919 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Oncology Research and Treatment, 2023. Verfasst von Bruno Almeida Costa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Icahn School of Medicine at Mount Sinai (Morningside/West), New York, New York, USA, bruno.costa@mountsinai.org. Hauptthemen laut MEDLINE: Klatskin Tumor, Ovarian Neoplasms, Bile Duct Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Despite major advances in surveillance and management, advanced cholangiocarcinoma (CCA) still carries a dismal prognosis. In recent years, several actionable genomic alterations in pancreatobiliary malignancies have been identified. For instance, homologous recombination deficiency (HRD) has been considered a predictive biomarker of clinical response to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. Case Report: A 53-year-old man with a stage 3 (T4N0M0) BRCA2-mutant CCA developed intolerable toxicity after 44 cycles of gemcitabine/cisplatin. In light of his HRD positivity, treatment was switched to single-agent olaparib. The patient showed a partial radiological response, which was maintained after 8 months of olaparib discontinuation (progression-free survival >36 months).

Conclusion

Given the durable response observed, olaparib can be a valuable therapeutic tool in BRCA-mutant CCAs. Ongoing and future clinical trials are needed to confirm the role of PARP inhibition in similar patients and to define the clinicopathological and molecular profile of the individuals most likely to benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klatskin TumorOvarian NeoplasmsBile Duct NeoplasmsMaleFemaleHumansMiddle AgedPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesBile Ducts, IntrahepaticMutationGerm CellsBRCA2 ProteinPhthalazinesPiperazines

Stichwörter der Autor:innen

BRCA2 mutationBiliary tract cancersCholangiocarcinomaOlaparibPARP inhibitorPersonalized medicine

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesBRCA2 ProteinolaparibPhthalazinesPiperazinesBRCA2 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Icahn School of Medicine at Mount Sinai (Morningside/West), New York, New York, USA, bruno.costa@mountsinai.org.
  • Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA.

Zitieren

APA

Costa, B. A., Tallón de Lara, P., Park, W., Keane, F., Harding, J. J., & Khalil, D. N. (2023). Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation. Oncology Research and Treatment. https://doi.org/10.1159/000529919

Vancouver

Costa BA, Tallón de Lara P, Park W, Keane F, Harding JJ, Khalil DN. Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation. Oncology Research and Treatment. 2023. doi:10.1159/000529919

BibTeX
@article{Costa2023,
  author = {Costa, Bruno Almeida and Tallón de Lara, Paulino and Park, Wungki and Keane, Fergus and Harding, James J and Khalil, Danny N},
  title = {Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation},
  journal = {Oncology Research and Treatment},
  year = {2023},
  doi = {10.1159/000529919}
}
Kostenlos starten →